Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 3Recruiting 2Not yet recruiting 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Breast 2Tumor-Agnostic 1

Conditions

Triple Negative Breast Neoplasms 1Neoplasms 1Breast Neoplasms 1

Interventions

Cisplatin 517Radiotherapy 378Cyclophosphamide 368Carboplatin 359Capecitabine 342Paclitaxel 337Oxaliplatin 336Gemcitabine 322Docetaxel 317Fluorouracil 291Drug Therapy 277Bevacizumab 249apatinib 247camrelizumab 219Etoposide 201Irinotecan 183Doxorubicin 181Leucovorin 164Dexamethasone 161pembrolizumab 155Neoadjuvant Therapy 146sintilimab 145anlotinib 140Blood Specimen Collection 140Pemetrexed 138Cytarabine 138toripalimab 133Surgical Procedures, Operative 131Radiosurgery 131S 1 (combination) 125

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × Sequence Analysis, RNA × Clear all
NCT04745975 2022-04-20

Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

Fudan University

Phase 2 Unknown
100 enrolled
Breast

Triple Negative Breast Neoplasms

NCT03521245 2021-09-14

Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer

OmicsWay Corp.

Unknown
40 enrolled
Breast

Breast Neoplasms

NCT03724097 2021-09-14

Identification of Molecular Biomarkers for Cancer Target Therapy Efficacy

OmicsWay Corp.

Unknown
200 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡